Search | IOVS | ARVO Journals

Showing 1 – 16 of 16

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2017

A novel structural variant in VIEW1 neovascular age-related macular degeneration (AMD) patients

Lorah T Perlee; Robert Vitti

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):894. doi:

ARVO Annual Meeting Abstract June 2017

Impact of baseline retinal nonperfusion on best corrected visual acuity in eyes with central retinal vein occlusion: post hoc analyses of COPERNICUS and GALILEO

David M Brown; Yuichiro Ogura; Francesco Boscia; Frank G Holz; Jean-Francois Korobelnik; Jeffrey Heier; Kay D Rittenhouse; Friedrich Asmus; Christiane Ahlers; Florian Hiemeyer; Chengxing Lu; Robert Vitti; Namrata Saroj; Nicolas Feltgen

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1559. doi:

ARVO Annual Meeting Abstract September 2016

Interim results from the SATURN Study: Sarilumab in Non-infectious Uveitis (SARIL-NIU)

Quan Dong Nguyen; Preethi A Sundaram; Kristine Erickson; Rafael Varona; Laetitia Vinet; Valerie Corp-dit-Genti; Robert Vitti; Marc D de Smet

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):1894. doi:

ARVO Annual Meeting Abstract September 2016

Systemic Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor (VEGF) Agents in Patients With Wet Age-Related Macular Degeneration

Peter K Kaiser; Laurent Kodjikian; Jean-Francois Korobelnik; Oliver Zeitz; Robert Vitti; Carola Metzig; Christiane Ahlers; Thomas dicioccio; Joachim Hoechel

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3366. doi:

ARVO Annual Meeting Abstract September 2016

Variability in vitreous haze grading technique using a 9-step logarithmic scale in patients enrolled in the Sarilumab in Non-infectious Uveitis (SARIL-NIU), the Saturn Study

Marc D de Smet; Preethi A Sundaram; Kristine Erickson; Valerie Corp-dit-Genti; Laetitia Vinet; Robert Vitti; Ronald BUGGAGE; Quan Dong Nguyen

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract June 2015

The SATURN Study (SARIL-NIU): Sarilumab for the Treatment of Posterior Segment Non-Infectious Uveitis (NIU)

Quan Dong Nguyen; Preethi A Sundaram; Kristine Erickson; Rafael varona; David Drouot; Valerie Corp-dit-Genti; Husain Kazmi; Robert Vitti; Marc D de Smet; SATURN Study Group

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3116. doi:

ARVO Annual Meeting Abstract April 2014

Efficacy and Safety of Intravitreal Aflibercept for Choroidal Neovascularization Secondary to Pathological Myopia: 48-week Results of MYRROR Study

Tien Y Wong; Tatsuro Ishibashi; Kyoko Ohno-Matsui; Yasushi Ikuno; Jean-Francois Korobelnik; Brigitte Stemper; Yoshimi Matsuda; Tummy Li; Robert Vitti; Oliver Zeitz; MYRROR

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):4960. doi:

ARVO Annual Meeting Abstract June 2013

Eighteen-Month Results of the GALILEO Study Evaluating Intravitreal Aflibercept Injection (IAI) for Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

Yuichiro Ogura; Jean-Francois Korobelnik; Johann Roider; Robert Vitti; Frank Holz; Florian Hiemeyer; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink; GALILEO study investigators

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4516. doi:

ARVO Annual Meeting Abstract March 2012

Intraocular Pressure in Patients with Neovascular AMD Receiving Intravitreal Aflibercept Injection or Ranibizumab

K Bailey Freund; Robert Vitti; Yuhwen Soo; Desmond Thompson; Namrata Saroj; Alyson J. Berliner; Majid Anderesi; Olaf Sowade; Rupert Sandbrink

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2036. doi:

ARVO Annual Meeting Abstract March 2012

Cumulative Incidence of Visual Acuity Change in the VIEW 1 and VIEW 2 Studies of Patients with Neovascular Age-related Macular Degeneration

Daniel B. Roth; Jeffrey S. Heier; Desmond Thompson; Yuhwen Soo; Robert Vitti; Namrata Saroj; Alyson J. Berliner; Georg Groeztbach; Olaf Sowade; Oliver Zeitz

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2042. doi:

ARVO Annual Meeting Abstract March 2012

Intravitrial Aflibercept Injection for Macular Edema in Central Retinal Vein Occlusion: 1-year Results of the Phase 3 GALILEO Study

Frank G. Holz; Yuichiro Ogura; Johann Roider; Jean-Francois Korobelnik; Brigitte Stemper; Robert Vitti; Alyson J. Berliner; Florian Hiemeyer; Rupert Sandbrink; Oliver Zeitz

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6929. doi:

ARVO Annual Meeting Abstract March 2012

Intravitreal Aflibercept Injection in Central Retinal Vein Occlusion: 1-year Results of the Phase 3 COPERNICUS Study

David M. Brown; Julia A. Haller; David S. Boyer; Jeffrey S. Heier; W. L. Clark; Alyson J. Berliner; Robert Vitti; Oliver Zeitz; Rupert Sandbrink

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):936. doi:

ARVO Annual Meeting Abstract March 2012

Microperimetry assessment of retinal sensitivity in patients with diabetic macular edema - results from the Phase 2 Da Vinci study

Victor H. Gonzalez; Diana V. Do; Husain Kazmi; Robert Vitti; Alyson J. Berliner; Georg Groetzbach; Rupert Sandbrink; Oliver Zeitz

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2863. doi:

ARVO Annual Meeting Abstract March 2012

Subgroup Efficacy Analyses of the VIEW 1 and VIEW 2 Studies of Intravitreal Aflibercept Injection and Ranibizumab for Treatment of Neovascular AMD

Allen C. Ho; Desmond Thompson; Robert Vitti; Yuhwen Soo; Alyson J. Berliner; Georg Groetzbach; Majid Anderesi; Rupert Sandbrink; Victor Chong; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):3678. doi:

ARVO Annual Meeting Abstract April 2011

Randomized, Double-masked, Active-controlled Phase 3 Trial Of The Efficacy And Safety Of Intravitreal VEGF Trap-Eye In Wet AMD: One-year Results Of The View-1 Study

Quan D. Nguyen; Jeffery Heier; David Brown; Allen Ho; Peter Kaiser; Robert Vitti; VIEW 1 Study Group

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3073. doi:

ARVO Annual Meeting Abstract April 2011

VEGF Trap-Eye In CRVO: Primary Endpoint Results Of The Phase 3 COPERNICUS Study

Julia A. Haller; David S. Boyer; Jeffrey S. Heier; David M. Brown; Lloyd Clark; Robert Vitti

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):6643. doi:

NARROW

Content Type

Journal

Article Type

Specify Date Range

A novel structural variant in VIEW1 neovascular age-related macular degeneration (AMD) patients

Impact of baseline retinal nonperfusion on best corrected visual acuity in eyes with central retinal vein occlusion: post hoc analyses of COPERNICUS and GALILEO

Interim results from the SATURN Study: Sarilumab in Non-infectious Uveitis (SARIL-NIU)

Systemic Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor (VEGF) Agents in Patients With Wet Age-Related Macular Degeneration

Variability in vitreous haze grading technique using a 9-step logarithmic scale in patients enrolled in the Sarilumab in Non-infectious Uveitis (SARIL-NIU), the Saturn Study

The SATURN Study (SARIL-NIU): Sarilumab for the Treatment of Posterior Segment Non-Infectious Uveitis (NIU)

Efficacy and Safety of Intravitreal Aflibercept for Choroidal Neovascularization Secondary to Pathological Myopia: 48-week Results of MYRROR Study

Eighteen-Month Results of the GALILEO Study Evaluating Intravitreal Aflibercept Injection (IAI) for Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

Intraocular Pressure in Patients with Neovascular AMD Receiving Intravitreal Aflibercept Injection or Ranibizumab

Cumulative Incidence of Visual Acuity Change in the VIEW 1 and VIEW 2 Studies of Patients with Neovascular Age-related Macular Degeneration

Intravitrial Aflibercept Injection for Macular Edema in Central Retinal Vein Occlusion: 1-year Results of the Phase 3 GALILEO Study

Intravitreal Aflibercept Injection in Central Retinal Vein Occlusion: 1-year Results of the Phase 3 COPERNICUS Study

Microperimetry assessment of retinal sensitivity in patients with diabetic macular edema - results from the Phase 2 Da Vinci study

Subgroup Efficacy Analyses of the VIEW 1 and VIEW 2 Studies of Intravitreal Aflibercept Injection and Ranibizumab for Treatment of Neovascular AMD

Randomized, Double-masked, Active-controlled Phase 3 Trial Of The Efficacy And Safety Of Intravitreal VEGF Trap-Eye In Wet AMD: One-year Results Of The View-1 Study

VEGF Trap-Eye In CRVO: Primary Endpoint Results Of The Phase 3 COPERNICUS Study

To View More...

You must be signed into an individual account to use this feature.